Free Trial

Intuitive Surgical (ISRG) Stock Price, News & Analysis

$492.63
+5.46 (+1.12%)
(As of 08/30/2024 ET)
Today's Range
$485.28
$493.44
50-Day Range
$416.14
$490.43
52-Week Range
$254.85
$493.97
Volume
1.10 million shs
Average Volume
1.52 million shs
Market Capitalization
$174.74 billion
P/E Ratio
88.92
Dividend Yield
N/A
Price Target
$446.45

Intuitive Surgical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
9.4% Downside
$446.45 Price Target
Short Interest
Healthy
1.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
0.78mentions of Intuitive Surgical in the last 14 days
Based on 39 Articles This Week
Insider Trading
Selling Shares
$26.28 M Sold Last Quarter
Proj. Earnings Growth
17.05%
From $5.22 to $6.11 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.54 out of 5 stars

Medical Sector

101st out of 940 stocks

Surgical Appliances & Supplies Industry

5th out of 16 stocks

ISRG stock logo

About Intuitive Surgical Stock (NASDAQ:ISRG)

Intuitive Surgical, Inc. is a leading medical technology company specializing in robotic-assisted surgical systems. Founded in 1995, the company's mission is to improve patient outcomes through the use of innovative technology and minimally invasive surgical techniques. Headquartered in Sunnyvale, California, Intuitive Surgical operates globally, serving healthcare professionals and patients in over 60 countries.

Intuitive Surgical's flagship product is the da Vinci Surgical System, a robotic platform that enables surgeons to perform complex procedures with enhanced precision, control, and visualization. The system consists of robotic arms controlled by the surgeon, along with a high-definition 3D camera and specialized surgical instruments. This advanced technology allows for smaller incisions, reduced scarring, shorter recovery times, and improved clinical outcomes.

The company's target market primarily includes hospitals and surgical centers specializing in urology, gynecology, general, and thoracic surgery. Intuitive Surgical has established itself as a leader in these fields and has a strong customer base, including prestigious medical institutions and renowned surgeons. The company's dedication to innovation and patient care has garnered numerous accolades, including recognition as one of Fortune's "World's Most Admired Companies" in the healthcare industry.

Intuitive Surgical is led by an experienced management team committed to driving the company's growth and maintaining its position as a leader in surgical robotics. Dr. Gary Guthart is the Chief Executive Officer and has been instrumental in guiding the company's strategic direction. Under his leadership, Intuitive Surgical has expanded its product portfolio, entered new markets, and achieved remarkable financial success.

Intuitive Surgical has consistently delivered strong financial performance over the past few years. The company's revenue has experienced steady growth, reaching $6.22 billion in the latest fiscal year. With a strong focus on operational efficiency, Intuitive Surgical has maintained healthy profit margins, enabling it to invest in research and development and expand its market reach.

The company has a solid balance sheet with manageable debt levels. This provides stability and financial flexibility for future investments and acquisitions. Intuitive Surgical's financial performance is notably impressive compared to industry benchmarks, reflecting its strong market position and competitive advantage.

Intuitive Surgical commands a premium compared to its industry peers. The company's price-to-earnings ratio, a commonly used valuation measure, is higher than average due to its strong growth prospects and dominant market position. Investors have recognized the company's innovation and potential for long-term success, contributing to its higher valuation.

Intuitive Surgical has exhibited remarkable stock performance in recent years. The company's share price has experienced significant growth, reflecting investor confidence in its business model and growth potential. Notably, the stock has outperformed broader market indices and many of its industry peers.

Intuitive Surgical operates in the rapidly evolving field of surgical robotics, which is transforming the healthcare landscape. The industry is characterized by intense competition, with major players including Medtronic, Johnson & Johnson, and Stryker Corporation. These companies continually invest in research and development to enhance their robotic surgical systems and expand their market presence.

Regulatory and political factors also play a significant role in the industry. Government agencies, such as the U.S. Food and Drug Administration (FDA), regulate the approval and safety of robotic surgical systems. Changes in regulations or introducing new policies can impact the industry landscape and market access for companies like Intuitive Surgical.

Despite the competitive landscape, Intuitive Surgical maintains a solid competitive advantage. The company's pioneering da Vinci Surgical System has established a dominant position in the market, with a large installed base worldwide. This gives Intuitive Surgical a significant edge in terms of customer loyalty and brand recognition. Additionally, the company's focus on continuous innovation and product development enables it to stay ahead of the competition.

Acquisitions and strategic partnerships offer growth opportunities for Intuitive Surgical. The company has a strong balance sheet enabling it to pursue strategic acquisitions that complement its existing product portfolio or provide access to new markets. Collaborating with other medical technology companies or research institutions can also fuel innovation and open doors to novel surgical solutions.

Like any company operating in the healthcare industry, Intuitive Surgical faces various risks and challenges. One significant risk is the potential for changes in healthcare policies and reimbursement rates. Government policies can directly impact the adoption and utilization of robotic surgical systems, which could affect the demand for Intuitive Surgical's products.

Another challenge is emerging new technologies or surgical techniques that may compete with or disrupt the robotic-assisted surgery market. Technological advancements in artificial intelligence and virtual reality could offer alternative solutions to traditional surgical procedures. Intuitive Surgical must stay at the forefront of innovation and adapt its offerings to remain competitive.

Additionally, the company faces the risk of product recalls or safety concerns. As robotic surgical systems become more complex, ensuring their reliability and patient safety becomes paramount. Intuitive Surgical must continue to invest in quality control measures, regulatory compliance, and ongoing training for surgeons to mitigate these risks.

ISRG Stock Price History

ISRG Stock News Headlines

Various icons of the companies belonging to the Facebook metaverse on the black screen of the smartphone.
3 Best Growth Stocks to Own for the Next 10 Years (ISRG)
When in doubt, zoom out; these three growth stocks have a history of strong performance that is likely to continue for the next 10 years
Ex-CIA Advisor: “This is How Kamala will Rig the Election”
A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…
Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Sells 396 Shares
AstraZeneca Covid-19 vaccine concept. Close-up of a syringe and and, the AstraZeneca company logo in the background.
Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs (ISRG)
AstraZeneca, T-Mobile US, and Intuitive Surgical are hitting all-time highs, driven by solid sector performance, robust earnings, and strategic advancements.
surgery robotic machine use allows doctors to perform many types of complex procedures
Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics? (ISRG)
Surgical robotics company PROCEPT BioRobotics Co. (NASDAQ: PRCT) developed the AquaBeam Robotic System for the treatment of benign prostatic hyperplasia
Medical robot. Robotic Surgery. Medical operation involving robot. robotic surgery with the robotic system
Why Intuitive Surgical Stock is Dominating the Medical Sector
Robotic surgery conjures up futuristic images of automated machines performing surgery on anesthetized human patients in an assembly line. However
Ex-CIA Advisor: “This is How Kamala will Rig the Election”
A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…
August 20, 2019, Brazil. In this photo illustration the Microsoft logo is displayed on a smartphone.
3 AI Stocks That You Can Buy and Hold Forever (ISRG)
These AI stocks are applying the technology and generating value today that will grow over time as the AI-supercycle unfolds.
2 Top Healthcare Growth Stocks to Buy Right Now
Intuitive Surgical (NASDAQ:ISRG) PT Raised to $494.00 at BTIG Research
Intuitive Surgical (NASDAQ:ISRG) Trading 0.4% Higher on Analyst Upgrade
See More Headlines
Receive ISRG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intuitive Surgical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/18/2024
Today
8/30/2024
Next Earnings (Estimated)
10/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ISRG
CUSIP
46120E60
Employees
13,676
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$446.45
High Stock Price Target
$560.00
Low Stock Price Target
$314.00
Potential Upside/Downside
-8.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
20 Analysts

Profitability

Net Income
$1.80 billion
Pretax Margin
29.46%

Debt

Sales & Book Value

Annual Sales
$7.57 billion
Cash Flow
$5.87 per share
Book Value
$41.64 per share

Miscellaneous

Free Float
351,508,000
Market Cap
$173.23 billion
Optionable
Optionable
Beta
1.39

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Should I Buy Intuitive Surgical Stock? ISRG Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Intuitive Surgical, Inc.:

  • Intuitive Surgical has a strong market capitalization of $170+ billion, indicating stability and potential for growth.
  • The company's PE ratio of 86.67 suggests a solid earnings performance relative to its stock price.
  • Intuitive Surgical's consistent revenue growth of 14.5% year-over-year demonstrates a healthy business trajectory.
  • The stock's 50-day and 200-day simple moving averages trending above the current stock price indicate positive momentum.
  • Analysts forecasting an earnings per share of 5.22 for the current fiscal year show confidence in the company's future profitability.

Cons

Investors should be bearish about investing in Intuitive Surgical, Inc. for these reasons:

  • The stock's PE ratio of 86.67 may indicate an overvalued position compared to industry peers.
  • Intuitive Surgical's price-to-earnings-growth ratio of 4.97 could suggest limited growth potential relative to its current valuation.
  • With a beta of 1.39, the stock is more volatile than the market average, posing higher risk for investors.
  • Intuitive Surgical's 1-year high of $480.54 may present a resistance level for further stock price appreciation.
  • Investors should carefully consider the stock's trading volume compared to its average volume for liquidity concerns.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 19, 2024. Please send any questions or comments about these Intuitive Surgical pros and cons to contact@marketbeat.com.

ISRG Stock Analysis - Frequently Asked Questions

How have ISRG shares performed this year?

Intuitive Surgical's stock was trading at $337.36 at the beginning of the year. Since then, ISRG shares have increased by 46.0% and is now trading at $492.63.
View the best growth stocks for 2024 here
.

How were Intuitive Surgical's earnings last quarter?

Intuitive Surgical, Inc. (NASDAQ:ISRG) announced its earnings results on Thursday, July, 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.54 by $0.24. The business's quarterly revenue was up 14.5% compared to the same quarter last year.
Read the conference call transcript
.

When did Intuitive Surgical's stock split?

Shares of Intuitive Surgical split on the morning of Tuesday, October 5th 2021. The 3-1 split was announced on Thursday, August 5th 2021. The newly issued shares were issued to shareholders after the market closes on Monday, October 4th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What is Gary S. Guthart's approval rating as Intuitive Surgical's CEO?

431 employees have rated Intuitive Surgical Chief Executive Officer Gary S. Guthart on Glassdoor.com. Gary S. Guthart has an approval rating of 99% among the company's employees. This puts Gary S. Guthart in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Does Intuitive Surgical have any subsidiaries?

Intuitive Surgical subsidiaries include these companies: Orpheus Medical, NeoGuide Systems, Computer Motion, Intuitive Surgical AB, Intuitive Surgical ApS, Intuitive Surgical Australia Proprietary Limited, Intuitive Surgical Brasil Importacao E Comercio De Equipamentos Cirurgicos Ltda, and more.

Who are Intuitive Surgical's major shareholders?

Top institutional investors of Intuitive Surgical include Austin Private Wealth LLC, Bank of New York Mellon Corp (1.60%), Baillie Gifford & Co. (1.08%) and Legal & General Group Plc (0.78%). Insiders that own company stock include David J Rosa, Marshall Mohr, Alan J Levy, Mark J Rubash, Amal M Johnson, Gary S Guthart, Robert Desantis, Henry L Charlton, Amy L Ladd, Myriam Curet, Mark Brosius, Fredrik Widman, Craig H Barratt and Jamie Samath.
View institutional ownership trends
.

How do I buy shares of Intuitive Surgical?

Shares of ISRG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Intuitive Surgical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intuitive Surgical investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Salesforce (CRM), PayPal (PYPL) and Walt Disney (DIS).

This page (NASDAQ:ISRG) was last updated on 8/30/2024 by MarketBeat.com Staff

From Our Partners